Latest Conference Articles

December 6th 2017, 10:48pm

San Antonio Breast Cancer Symposium

A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

December 2nd 2017, 5:00am

SUO Annual Meeting

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

December 2nd 2017, 3:47am

SUO Annual Meeting

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

December 2nd 2017, 2:06am

SUO Annual Meeting

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

December 1st 2017, 9:53pm

SUO Annual Meeting

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

December 1st 2017, 9:48pm

SUO Annual Meeting

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

December 1st 2017, 5:00am

SUO Annual Meeting

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

December 1st 2017, 3:07am

SUO Annual Meeting

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

December 1st 2017, 1:31am

SUO Annual Meeting

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses current clinical trials in penile cancer.

December 1st 2017, 1:22am

SUO Annual Meeting

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.

December 1st 2017, 12:12am

SUO Annual Meeting

It has been a landmark year for immunotherapy in bladder cancer with the approval of 5 checkpoint inhibitors across first and second line.

November 30th 2017, 7:12am

SUO Annual Meeting

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.

November 30th 2017, 6:11am

SUO Annual Meeting

Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.

November 30th 2017, 4:20am

SUO Annual Meeting

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

November 30th 2017, 4:20am

SUO Annual Meeting

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

November 30th 2017, 3:27am

SUO Annual Meeting

Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.

November 20th 2017, 1:42am

EMUC Congress

Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.

November 20th 2017, 1:40am

EMUC Congress

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

November 19th 2017, 9:50pm

EMUC Congress

Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

November 19th 2017, 9:37pm

EMUC Congress

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.